Lyme Borreliosis in Dogs and Cats: Background, Diagnosis, Treatment and Prevention of Infections with Borrelia burgdorferi sensu stricto

Veterinary Clinics of North America - Small Animal Practice

Volumn 40, Issue 6, 2010, Pages 1103-1119

  Krupka, Inke ^a   Straubinger, Reinhard K ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Borrelia; Dog; Lyme borreliosis; Lyme disease; Tick

Indexed keywords

ACARICIDE; AMITRAZ; AMOXICILLIN; AZITHROMYCIN; BACTERIUM ANTIBODY; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; DOXYCYCLINE; FIPRONIL; GLUCOCORTICOID; INSECT REPELLENT; LYME DISEASE VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G;

ANAMNESIS; ANAPLASMA PHAGOCYTOPHILUM; ANIMAL LAMENESS; ANTIBODY DETECTION; ANTIMICROBIAL THERAPY; ARTHRITIS; BACTERIAL SURVIVAL; BACTERIAL TRANSMISSION; BORRELIA BURGDORFERI; CAT; CLINICAL FEATURE; DISEASE CARRIER; DISEASE COURSE; DOG; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HABITAT; IMMUNE RESPONSE; IMMUNOBLOTTING; LABORATORY TEST; LYME DISEASE; MIXED INFECTION; NONHUMAN; NORTH AMERICA; POLYARTHRITIS; REVIEW; SEROLOGY; TAXONOMY; TICK BITE; TREATMENT DURATION; UNITED STATES;

ANIMALS; BORRELIA BURGDORFERI; CAT DISEASES; CATS; DOG DISEASES; DOGS; LYME DISEASE;

ANIMALIA; BACTERIA (MICROORGANISMS); BORRELIA; BORRELIA BURGDORFERI; CANIS FAMILIARIS; IXODIDA;

EID: 77957376245     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2010.07.011     Document Type: Review

References (74)

1. Haupt K., Kraiczy P., Wallich R., et al. Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis 2007, 196(1):124-133.
2. Rudenko N., Golovchenko M., Grubhoffer L., et al. Borrelia carolinensis sp.nov. - a new (14th) member of Borrelia burgdorferi sensu lato complex from the southeastern United States. J Clin Microbiol 2009, 47(1):134-141.
3. Rudenko N., Golovchenko M., Lin T., et al. Delineation of a new species of the Borrelia burgdorferi sensu lato complex, Borrelia americana sp. J Clin Microbiol 2009, 47(12):3875-3880.
4. Postic D., Garnier M., Baranton G. Multilocus sequence analysis of atypical Borrelia burgdorferi sensu lato isolates-description of Borrelia californiensis sp. nov., and genomospecies 1 and 2. Int J Med Microbiol 2007, 297(4):263-271.
5. Steere A.C. Lyme disease. N Engl J Med 2001, 345(2):115-125.
6. Appel M.J. Lyme disease in dogs and cats. Compend Cont Educ Pract Vet 1990, 12:617-626.
7. Hovius K.E., Stark L.A., Bleumink-Pluym N.M., et al. Presence and distribution of Borrelia burgdorferi sensu lato species in internal organs and skin of naturally infected symptomatic and asymptomatic dogs, as detected by polymerase chain reaction. Vet Q 1999, 21(2):54-58.
8. Speck S., Reiner B., Wittenbrink M.M. Isolation of Borrelia afzelii from a dog. Vet Rec 2001, 149(1):19-20.
9. Fingerle V., Schulte-Spechtel U.C., Ruzic-Sabljic E., et al. Epidemiological aspects and molecular characterization of Borrelia burgdorferi s.l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov. Int J Med Microbiol 2008, 298(3-4):279-290.
10. Greene C.E., Straubinger R.K. Borreliosis. Infectious diseases of the dog and cat 2006, 417-435. WB Saunders Elsevier, Philadelphia. 3rd edition. C.E. Greene (Ed.).
11. Rauter C., Hartung T. Prevalence of Borrelia burgdorferi sensu lato genospecies in Ixodes ricinus ticks in Europe: a metaanalysis. Appl Environ Microbiol 2005, 71(11):7203-7216.
12. Ogden N.H., Nuttall P.A., Randolph S.E. Natural Lyme disease cycles maintained via sheep by co-feeding ticks. Parasitology 1997, 11:5591-5599.
13. Nefedova V.V., Korenberg E.I., Gorelova N.B., et al. Studies on the transovarial transmission of Borrelia burgdorferi sensu lato in the taiga tick Ixodes persulcatus. Folia Parasitol (Praha) 2004, 51(1):67-71.
14. Gustafson J.M., Burgess E.C., Wachal M.D., et al. Intrauterine transmission of Borrelia burgdorferi in dogs. Am J Vet Res 1993, 54(6):882-890.
15. Appel M.J., Allen S., Jacobson R.H., et al. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis 1993, 167:651-664.
16. Straubinger R.K., Straubinger A.F., Summers B.A., et al. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study. J Infect Dis 2000, 181(3):1069-1081.
17. Schwan T.G., Piesman J., Golde W.T., et al. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci U S A 1995, 92(7):2909-2913.
18. Wilske B., Busch U., Fingerle V., et al. Immunological and molecular variability of OspA and OspC. Implication for Borrelia vaccine development. Infection 1996, 24(2):208-212.
19. Ohnishi J., Piesman J., de Silva A.M. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. Proc Natl Acad Sci U S A 2001, 98(2):670-675.
20. Grimm D., Tilly K., Byram R., et al. Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals. Proc Natl Acad Sci U S A 2004, 101(9):3142-3147.
21. Templeton T.J. Borrelia outer membrane surface proteins and transmission through the tick. J Exp Med 2004, 199(5):603-606.
22. Schuijt T.J., Hovius J.W., van Burgel N.D., et al. Salp15 inhibits the killing of serum sensitive Borrelia burgdorferi sensu lato isolates. Infect Immun 2008.
23. Piesman J., Dolan M.C., Happ C.M., et al. Duration of immunity to reinfection with tick-transmitted Borrelia burgdorferi in naturally infected mice. Infect Immun 1997, 65(10):4043-4047.
24. Nadelman R.B., Sherer C., Mack L., et al. Survival of Borrelia burgdorferi in human blood stored under blood banking conditions. Transfusion 1990, 30(4):298-301.
25. Straubinger R.K., Straubinger A.F., Summers B.A., et al. Clinical manifestations, pathogenesis, and effect of antibiotic treatment on Lyme borreliosis in dogs. Wien Klin Wochenschr 1998, 110(24):874-881.
26. Fraser C.M., Casjens S., Huang W.M., et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 1997, 390(6660):580-586.
27. Klempner M.S., Noring R., Epstein M.P., et al. Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi. J Infect Dis 1995, 17:11258-11265.
28. Takayama K., Rothenberg R.J., Barbour A.G. Absence of lipopolysaccharide in the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1987, 55(9):2311-2313.
29. Embers M.E., Liang F.T., Howell J.K., et al. Antigenicity and recombination of VlsE, the antigenic variation protein of Borrelia burgdorferi, in rabbits, a host putatively resistant to long-term infection with this spirochete. FEMS Immunol Med Microbiol 2007, 50(3):421-429.
30. Coutte L., Botkin D.J., Gao L., et al. Detailed analysis of sequence changes occurring during vlsE antigenic variation in the mouse model of Borrelia burgdorferi infection. PLoS Pathog 2009, 5(2). e1000293.
31. Indest K.J., Howell J.K., Jacobs M.B., et al. Analysis of Borrelia burgdorferi vlsE gene expression and recombination in the tick vector. Infect Immun 2001, 69(11):7083-7090.
32. Zhang J.R., Norris S.J. Kinetics and in vivo induction of genetic variation of vlsE in Borrelia burgdorferi. Infect Immun 1998, 66(8):3689-3697.
33. Liang F.T., Philipp M.T. Analysis of antibody response to invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi. Infect Immun 1999, 67(12):6702-6706.
34. Gruntar I., Malovrh T., Murgia R., et al. Conversion of Borrelia garinii cystic forms to motile spirochetes in vivo. APMIS 2001, 109(5):383-388.
35. Lusitani D., Malawista S.E., Montgomery R.R. Calprotectin, an abundant cytosolic protein from human polymorphonuclear leukocytes, inhibits the growth of Borrelia burgdorferi. Infect Immun 2003, 71(8):4711-4716.
36. Montgomery R.R., Nathanson M.H., Malawista S.E. Fc- and non-Fc-mediated phagocytosis of Borrelia burgdorferi by macrophages. J Infect Dis 1994, 170:890-893.
37. Craft J.E., Grodzicki R.L., Shrestha M., et al. The antibody response in Lyme disease. Yale J Biol Med 1984, 57(4):561-565.
38. Straubinger R.K., Straubinger A.F., Harter L., et al. Borrelia burgdorferi migrates into joint capsules and causes an up-regulation of interleukin-8 in synovial membranes of dogs experimentally infected with ticks. Infect Immun 1997, 65(4):1273-1285.
39. Lazarus J.J., Kay M.A., McCarter A.L., et al. Viable Borrelia burgdorferi enhances interleukin-10 production and suppresses activation of murine macrophages. Infect Immun 2008, 76(3):1153-1162.
40. Kalish R.A., Leong J.M., Steere A.C. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 1993, 612:774-779.
41. Straubinger R.K., Summers B.A., Chang Y.F., et al. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 1997, 35(1):111-116.
42. Muir P., Oldenhoff W.E., Hudson A.P., et al. Detection of DNA from a range of bacterial species in the knee joints of dogs with inflammatory knee arthritis and associated degenerative anterior cruciate ligament rupture. Microb Pathog 2007, 42(2-3):47-55.
43. Grauer G.F., Burgess E.C., Cooley A.J., et al. Renal lesions associated with Borrelia burgdorferi infection in a dog. J Am Vet Med Assoc 1988, 193(2):237-239.
44. Dambach D.M., Smith C.A., Lewis R.M., et al. Morphologic, immunohistochemical, and ultrastructural characterization of a distinctive renal lesion in dogs putatively associated with Borrelia burgdorferi infection: 49 cases (1987-1992). Vet Pathol 1997, 34:85-96.
45. Gerber B., Eichenberger S., Wittenbrink M.M., et al. Increased prevalence of Borrelia burgdorferi infections in Bernese Mountain Dogs: a possible breed predisposition. BMC Vet Res 2007, 3(1):15.
46. Gerber B., Eichenberger S., Haug K., et al. Schweiz Arch Tierheilkd 2009, 151(10):479-483. [in German].
47. Halperin J.J. Nervous system Lyme disease. Infect Dis Clin North Am 2008, 22(2):261-274.
48. Vianello M., Marchiori G., Giometto B. Multiple cranial nerve involvement in Bannwarth's syndrome. Neurol Sci 2008, 29(2):109-112.
49. Pachner A.R., Steiner I. Lyme neuroborreliosis: infection, immunity, and inflammation. Lancet Neurol 2007, 6(6):544-552.
50. Levy S.A., Duray P.H. Complete heart block in a dog seropositive for Borrelia burgdorferi. J Vet Intern Med 1988, 21:38-44.
51. Greig B., Armstrong P.J. Canine granulocytotropic anaplasmosis (A phagocytophilum). Infectious diseases of the dog and cat 2006, 219-224. Saunders Elsevier, Philadelphia. 3rd edition. C.E. Greene (Ed.).
52. Bowman D., Little S.E., Lorentzen L., et al. Prevalence and geographic distribution of Dirofilaria immitis, Borrelia burgdorferi, Ehrlichia canis, and Anaplasma phagocytophilum in dogs in the United States: results of a national clinic-based serologic survey. Vet Parasitol 2009, 160(1-2):138-148.
53. Beall M., Chandrashekar R., Eberts M., et al. Borrelia burgdorferi and Anaplasma phagocytophilum: potential implications of co-infection on clinical presentation in the dog. J Vet Intern Med 2006, 20(No.3):713-714.
54. Gibson M.D., Omran M.T., Young C.R. Experimental feline Lyme borreliosis as a model for testing Borrelia burgdorferi vaccines. Adv Exp Med Biol 1995, 38:373-382.
55. Magnarelli L.A., Bushmich S.L., IJdo J.W., et al. Seroprevalence of antibodies against Borrelia burgdorferi and Anaplasma phagocytophilum in cats. Am J Vet Res 2005, 66(11):1895-1899.
56. Bruckbauer H.R., Preac-Mursic V., Fuchs R., et al. Cross-reactive proteins of Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 1992, 11(3):224-232.
57. Steere A.C., McHugh G., Damle N., et al. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 2008, 47(2):188-195.
58. Toepfer K.H., Straubinger R.K. Characterization of the humoral immune response in dogs after vaccination against the Lyme borreliosis agent A study with five commercial vaccines using two different vaccination schedules. Vaccine 2007, 25(2):314-326.
59. Hauser U., Lehnert G., Lobentanzer R., et al. Interpretation criteria for standardized Western blots for three European species of Borrelia burgdorferi sensu lato. J Clin Microbiol 1997, 35(6):1433-1444.
60. Hauser U., Lehnert G., Wilske B. Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe. J Clin Microbiol 1999, 37(7):2241-2247.
61. Greene R.T., Walker R.L., Nicholson W.L., et al. Immunoblot analysis of immunoglobulin G to the Lyme disease agent (Borrelia burgdorferi) in experimentally and naturally infected dogs. J Clin Microbiol 1988, 26:648-653.
62. Liang F.T., Aberer E., Cinco M., et al. Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL. J Infect Dis 2000, 182(5):1455-1462.
63. Liang F.T., Steere A.C., Marques A.R., et al. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J Clin Microbiol 1999, 37(12):3990-3996.
64. Levy S.A. Use of a C6 ELISA test to evaluate the efficacy of a whole-cell bacterin for the prevention of naturally transmitted canine Borrelia burgdorferi infection. Vet Ther 2002, 3(4):420-424.
65. Liang F.T., Jacobson R.H., Straubinger R.K., et al. Characterization of a Borrelia burgdorferi VlsE invariable region useful in canine Lyme disease serodiagnosis by enzyme-linked immunosorbent assay. J Clin Microbiol 2000, 38(11):4160-4166.
66. Philipp M.T., Bowers L.C., Fawcett P.T., et al. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J Infect Dis 2001, 184(7):870-878.
67. Levy S.A., O'Connor T.P., Hanscom J.L., et al. Quantitative measurement of C6 antibody following antibiotic treatment of Borrelia burgdorferi antibody positive nonclinical dogs. Clin Vaccine Immunol 2008, 15(1):115-119.
68. Eschner A.K. Effect of passive immunoglobulin transfer on results of diagnostic tests for antibodies against Borrelia burgdorferi in pups born to a seropositive dam. Vet Ther 2008, 9(3):184-191.
69. Straubinger R.K. PCR-Based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-day postinfection period. J Clin Microbiol 2000, 38(6):2191-2199.
70. Littman M.P. Canine borreliosis. Vet Clin North Am Small Anim Pract 2003, 33(4):827-862.
71. Littman M.P., Goldstein R.E., Labato M.A., et al. ACVIM small animal consensus statement on Lyme disease in dogs: diagnosis, treatment, and prevention. J Vet Intern Med 2006, 20(2):422-434.
72. Logigian E.L., Kaplan R.F., Steere A.C. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999, 180(2):377-383.
73. de Silva A.M., Fish D., Burkot T.R., et al. OspA antibodies inhibit the acquisition of Borrelia burgdorferi by Ixodes ticks. Infect Immun 1997, 65(8):3146-3150.
74. de Silva A.M., Telford S.R., Brunet L.R., et al. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med 1996, 183(1):271-275.